Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

37 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Tolerability of adjuvant high-dose interferon alfa-2b: 1 month versus 1 year--a Hellenic Cooperative Oncology Group study.
Gogas H, Bafaloukos D, Ioannovich J, Skarlos D, Polyzos A, Fountzilas G, Kalofonos HP, Aravantinos G, Tsoutsos D, Panagiotou P, Frangia K, Petrakopoulou T, Pectasides D; Hellenic Coperative Oncology Group. Gogas H, et al. Among authors: panagiotou p. Anticancer Res. 2004 May-Jun;24(3b):1947-52. Anticancer Res. 2004. PMID: 15274382 Free article. Clinical Trial.
Prognostic significance of autoimmunity during treatment of melanoma with interferon.
Gogas H, Ioannovich J, Dafni U, Stavropoulou-Giokas C, Frangia K, Tsoutsos D, Panagiotou P, Polyzos A, Papadopoulos O, Stratigos A, Markopoulos C, Bafaloukos D, Pectasides D, Fountzilas G, Kirkwood JM. Gogas H, et al. Among authors: panagiotou p. N Engl J Med. 2006 Feb 16;354(7):709-18. doi: 10.1056/NEJMoa053007. N Engl J Med. 2006. PMID: 16481638 Free article. Clinical Trial.
Evaluation of six CTLA-4 polymorphisms in high-risk melanoma patients receiving adjuvant interferon therapy in the He13A/98 multicenter trial.
Gogas H, Dafni U, Koon H, Spyropoulou-Vlachou M, Metaxas Y, Buchbinder E, Pectasides E, Tsoutsos D, Polyzos A, Stratigos A, Markopoulos C, Panagiotou P, Fountzilas G, Castana O, Skarlos P, Atkins MB, Kirkwood JM. Gogas H, et al. Among authors: panagiotou p. J Transl Med. 2010 Nov 3;8:108. doi: 10.1186/1479-5876-8-108. J Transl Med. 2010. PMID: 21044351 Free PMC article.
Vinorelbine in combination with interleukin-2 as second-line treatment in patients with metastatic melanoma. A phase II study of the Hellenic Cooperative Oncology Group.
Gogas H, Bafaloukos D, Aravantinos G, Fountzilas G, Tsoutsos D, Panagiotou P, Frangia K, Kalofonos HP, Briasoulis E, Castana O, Polyzos A, Pectasides D, Ioannovich J; Hellenic Cooperative Oncology Group. Gogas H, et al. Among authors: panagiotou p. Cancer Invest. 2004;22(6):832-9. doi: 10.1081/cnv-200039630. Cancer Invest. 2004. PMID: 15641480 Clinical Trial.
Randomized phase III study of 1 month versus 1 year of adjuvant high-dose interferon alfa-2b in patients with resected high-risk melanoma.
Pectasides D, Dafni U, Bafaloukos D, Skarlos D, Polyzos A, Tsoutsos D, Kalofonos H, Fountzilas G, Panagiotou P, Kokkalis G, Papadopoulos O, Castana O, Papadopoulos S, Stavrinidis E, Vourli G, Ioannovich J, Gogas H. Pectasides D, et al. Among authors: panagiotou p. J Clin Oncol. 2009 Feb 20;27(6):939-44. doi: 10.1200/JCO.2008.16.3121. Epub 2009 Jan 12. J Clin Oncol. 2009. PMID: 19139440 Clinical Trial.
A new mathematical model for the interpretation of translational research evaluating six CTLA-4 polymorphisms in high-risk melanoma patients receiving adjuvant interferon.
Pancoska P, Kirkwood JM, Bouros S, Spyropoulou-Vlachou M, Pectasides E, Tsoutsos D, Polyzos A, Markopoulos C, Panagiotou P, Castana O, Bafaloukos D, Fountzilas G, Gogas H. Pancoska P, et al. Among authors: panagiotou p. PLoS One. 2014 Jan 27;9(1):e86375. doi: 10.1371/journal.pone.0086375. eCollection 2014. PLoS One. 2014. PMID: 24475110 Free PMC article.
Temozolomide in combination with celecoxib in patients with advanced melanoma. A phase II study of the Hellenic Cooperative Oncology Group.
Gogas H, Polyzos A, Stavrinidis I, Frangia K, Tsoutsos D, Panagiotou P, Markopoulos C, Papadopoulos O, Pectasides D, Mantzourani M, Middleton M, Vaiopoulos G, Fountzilas G. Gogas H, et al. Among authors: panagiotou p. Ann Oncol. 2006 Dec;17(12):1835-41. doi: 10.1093/annonc/mdl311. Epub 2006 Sep 15. Ann Oncol. 2006. PMID: 16980601 Free article. Clinical Trial.
p53 codon 72 Pro homozygosity increases the risk of cutaneous melanoma in individuals with dark skin complexion and among noncarriers of melanocortin 1 receptor red hair variants.
Stefanaki I, Stratigos AJ, Dimisianos G, Nikolaou V, Papadopoulos O, Polydorou D, Gogas H, Tsoutsos D, Panagiotou P, Kanavakis E, Antoniou C, Katsambas AD. Stefanaki I, et al. Among authors: panagiotou p. Br J Dermatol. 2007 Feb;156(2):357-62. doi: 10.1111/j.1365-2133.2006.07645.x. Br J Dermatol. 2007. PMID: 17223878
37 results